Bullfrog AI Holdings, Inc. (BFRG)
| Market Cap | 11.01M -26.9% |
| Revenue (ttm) | 298,798 +798.5% |
| Net Income | -6.00M |
| EPS | -0.45 |
| Shares Out | 18.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 537,893 |
| Open | 0.6045 |
| Previous Close | 0.6175 |
| Day's Range | 0.5801 - 0.6299 |
| 52-Week Range | 0.4251 - 2.0400 |
| Beta | -2.72 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About BFRG
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebend... [Read more]
Financial Performance
Financial StatementsNews
Bullfrog AI Holdings Slides: Corporate presentation
Bullfrog AI Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
BullFrog AI to Participate in September 2026 Investor Conferences
GAITHERSBURG, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn co...
Bullfrog AI Holdings Quarterly report: Q2 2026
Bullfrog AI Holdings has published its Q2 2026 quarterly earnings report on August 14, 2026.
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn com...
BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026
GAITHERSBURG, Md., July 21, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn com...
Water Tower Research Publishes Initiation of Coverage Report on BullFrog AI Holdings, Inc., "Helping Big Pharma Look Before It Leaps in Drug Discovery"
June 24, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on BullFrog AI Holdings, Inc. (NASDAQ: BFRG) titled, “Helping Big P...
BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
GAITHERSBURG, Md., June 02, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and ma...
Bullfrog AI Holdings Registration statement: Registration filing
Bullfrog AI Holdings filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Bullfrog AI Holdings Quarterly report: Q1 2026
Bullfrog AI Holdings has published its Q1 2026 quarterly earnings report on May 14, 2026.
Bullfrog AI Holdings Proxy statement: Proxy filing
Bullfrog AI Holdings filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Bullfrog AI Holdings Proxy statement: Proxy filing
Bullfrog AI Holdings filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and m...
BullFrog AI Announces Participation at AACR Annual Meeting
BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957 BullFrog AI team will be available to discuss its end-to-end drug discovery and devel...
BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners
GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and machine ...
Bullfrog AI stock offers a rare opportunity for investors to take profit
Bullfrog AI Inc more than doubled on Mar. 30 after announcing a landmark commercial agreement with a “top 5” pharma leader to identify novel therapeutic targets for Major Depressive Disorder. In its p...
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
GAITHERSBURG, Md., March 30, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and m...
BullFrog AI Unveils bfARENAS™ Scenario-based Decision Engine
Completes end-to-end AI intelligence workflow product with an advanced AI decision tool that clearly defines drug target discovery and clinical trial strategies to build diversified, risk-balanced R&D...
Bullfrog AI Holdings Annual report: Q4 2025
Bullfrog AI Holdings has published its Q4 2025 annual report on March 19, 2026.
BullFrog to Host Webinar on New Precision AI Capability
March 27 webinar at 11 a.m. ET highlights launch of BullFrog AI's new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design March 27 webinar at 11 a.m. ET high...
BullFrog AI to Unveil New Precision AI Capability
GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and ma...
BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer
Company's bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI Company's bfLEAP® pl...
Bullfrog AI Holdings Quarterly report: Q3 2025
Bullfrog AI Holdings has published its Q3 2025 quarterly earnings report on November 14, 2025.
Bullfrog AI Holdings Registration statement: Registration filing
Bullfrog AI Holdings filed a registration statement on October 10, 2025, providing details about a securities offering with the SEC.
Bullfrog AI Holdings Proxy statement: Proxy filing
Bullfrog AI Holdings filed a proxy statement on September 26, 2025, providing details for shareholder voting and corporate governance matters.
Bullfrog AI Holdings Proxy statement: Proxy filing
Bullfrog AI Holdings filed a proxy statement on September 16, 2025, providing details for shareholder voting and corporate governance matters.